New Strategies to Target the TGF-?/Smad Signaling Pathway in Cancer | OMICS International | Abstract
ISSN: 2576-3881

Journal of Cytokine Biology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

New Strategies to Target the TGF-?/Smad Signaling Pathway in Cancer

*Corresponding Author:

Copyright: © 0  . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

To read the full article Peer-reviewed Article PDF image


The Transforming Growth Factor (TGF)-β signaling pathway governs key cellular processes under physiologic conditions and is deregulated in many pathologies, including cancer. TGF-β is a ubiquitous, multifunctional cytokine secreted by nearly all cell types that binds transmembrane TGF-β type I and II receptors to activate downstream pathways through intercellular SMAD transcriptional effectors. Deregulated inter-and intracellular TGF-β signaling contributes to cancer initiation and progression. In healthy cells and early stage cancers, TGF-β arrests epithelial growth and functions as a tumor suppressor. Later, after cancers have progressed, the cytostatic effects of TGF-β are circumvented, and TGF-β signaling exerts tumor promoting activities. TGF-β has been shown to induce epithelial-to-mesenchymal transition, stimulate angiogenesis, and contribute to immune evasion [1-3]. Collectively, the pleiotropic nature of TGF-β signaling contributes to drug resistance, tumor escape and undermines clinical response to therapy. Thus, based upon a wealth of preclinical and translational studies, the TGF-β signaling pathway has emerged as a highly attractive, actionable target that can be pharmacologically modulated to reduce tumor growth and improve the outcomes of cancer patients. Here, we comment on recent exciting and highly promising strategies that have been employed to target the TGF-β signaling pathway.